TP53 and lung carcinoma: Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors <i>via</i> a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance.